Genscript Biotech (HKG:1548) subsidiary Legend Biotech said one-third of patients with relapsed/refractory multiple myeloma in its ciltacabtagene autoleucel study showed progression-free survival for five years or more.
The cancer drug company showcased the results of its study at the 2025 American Society of Clinical Oncology conference, according to a Tuesday filing with the US Securities and Exchange Commission.
The patients who underwent the study were given a single dose of Carvykti without maintenance or subsequent myeloma therapy, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.